167 related articles for article (PubMed ID: 38485561)
1. Immune-mediated hepatitis: Basic concepts and treatment.
Velarde-Ruiz Velasco JA; Tapia Calderón DK; Cerpa-Cruz S; Velarde-Chávez JA; Uribe Martínez JF; García Jiménez ES; Aldana Ledesma JM; Díaz-González Á; Crespo J
Rev Gastroenterol Mex (Engl Ed); 2024; 89(1):106-120. PubMed ID: 38485561
[TBL] [Abstract][Full Text] [Related]
2. Hepatobiliary and Pancreatic Adverse Events.
Zhang HC; Wang LS; Miller E
Adv Exp Med Biol; 2021; 1342():339-355. PubMed ID: 34972973
[TBL] [Abstract][Full Text] [Related]
3. Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives.
Liu Z; Zhu Y; Xie H; Zou Z
Front Pharmacol; 2022; 13():1077468. PubMed ID: 36699050
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies.
Jennings JJ; Mandaliya R; Nakshabandi A; Lewis JH
Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):231-244. PubMed ID: 30677306
[TBL] [Abstract][Full Text] [Related]
5. [Pathological features of immune-mediated hepatitis due to immune checkpoint inhibitors and anti-angiogenesis targeted therapy].
Zhang QY; Chen LL; Gao F; Sujie A; Hou YY; Huang XW; Huang C; Sun HC; Zhou J; Ji Y
Zhonghua Bing Li Xue Za Zhi; 2020 Apr; 49(4):329-335. PubMed ID: 32268669
[No Abstract] [Full Text] [Related]
6. The ABC of Immune-Mediated Hepatitis during Immunotherapy in Patients with Cancer: From Pathogenesis to Multidisciplinary Management.
Lasagna A; Sacchi P
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398187
[TBL] [Abstract][Full Text] [Related]
7. Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review.
Juan-Carpena G; Palazón-Cabanes JC; Blanes-Martínez M
Actas Dermosifiliogr; 2022 Apr; 113(4):376-387. PubMed ID: 35623728
[TBL] [Abstract][Full Text] [Related]
8. Sarcoid-like Reactions to Immune Checkpoint Inhibitors.
Torrecilla-Vall-Llossera C; Jucglà Serra A; Molinero Caturla J; Moreno-Vílchez C; Penín Mosquera RM; Marcoval Caus J
Actas Dermosifiliogr; 2024 Jan; 115(1):80-83. PubMed ID: 37482293
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors-Induced Hepatitis.
Tian Y; Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2018; 995():159-164. PubMed ID: 30539511
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team.
Fan C; Kim A; Li S; Naidoo J; Cappelli LC; Brahmer JR; Anders RA; Kim AK
J Cancer Res Clin Oncol; 2023 Feb; 149(2):877-883. PubMed ID: 36102989
[TBL] [Abstract][Full Text] [Related]
11. Morphology of immune-mediated hepatitis: A comparison between immune checkpoint inhibitor therapy and combined immune checkpoint inhibitor/anti-angiogenic therapy.
Zhang Q; Chen L; Guo X; Shen L; Huang Y; Chen Y; Zhang N; Ge N; Gao H; Zhang W; Hou Y; Ji Y
Ann Diagn Pathol; 2024 Feb; 68():152225. PubMed ID: 38016303
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
Celsa C; Cabibbo G; Fulgenzi CAM; Scheiner B; D'Alessio A; Manfredi GF; Nishida N; Ang C; Marron TU; Saeed A; Wietharn B; Pinter M; Cheon J; Huang YH; Lee PC; Phen S; Gampa A; Pillai A; Vivaldi C; Salani F; Masi G; Roehlen N; Thimme R; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; El Tomb P; Ulahannan S; Parisi A; Chon HJ; Hsu WF; Stefanini B; Verzoni E; Giusti R; Veccia A; Catino A; Aprile G; Guglielmini PF; Di Napoli M; Ermacora P; Antonuzzo L; Rossi E; Verderame F; Zustovich F; Ficorella C; Di Pietro FR; Battelli N; Negrini G; Grossi F; Bordonaro R; Pipitone S; Banzi M; Ricciardi S; Laera L; Russo A; De Giorgi U; Cavanna L; Sorarù M; Montesarchio V; Bordi P; Brunetti L; Pinto C; Bersanelli M; Cammà C; Cortellini A; Pinato DJ
J Hepatol; 2024 Mar; 80(3):431-442. PubMed ID: 37972660
[TBL] [Abstract][Full Text] [Related]
13. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
14. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU.
Riveiro-Barciela M; Carballal S; Díaz-González Á; Mañosa M; Gallego-Plazas J; Cubiella J; Jiménez-Fonseca P; Varela M; Menchén L; Sangro B; Fernández-Montes A; Mesonero F; Rodríguez-Gandía MÁ; Rivera F; Londoño MC
Gastroenterol Hepatol; 2024 Apr; 47(4):401-432. PubMed ID: 38228461
[TBL] [Abstract][Full Text] [Related]
15. Hepatobiliary Adverse Events.
Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2020; 1244():271-276. PubMed ID: 32301021
[TBL] [Abstract][Full Text] [Related]
16. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation.
Peeraphatdit TB; Wang J; Odenwald MA; Hu S; Hart J; Charlton MR
Hepatology; 2020 Jul; 72(1):315-329. PubMed ID: 32167613
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.
Dougan M
Curr Gastroenterol Rep; 2020 Mar; 22(4):15. PubMed ID: 32185493
[TBL] [Abstract][Full Text] [Related]
18. [Emphasis on targeted and immunotherapy for liver injury in hepatocellular carcinoma].
Nan YM; Liu LD; Zhao SX
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1121-1124. PubMed ID: 38238942
[TBL] [Abstract][Full Text] [Related]
19. Rheumatological adverse events secondary to immune checkpoint inhibitors.
Garbarino MC; Manzano N; Messina O; Zylberman M
Reumatol Clin (Engl Ed); 2023 Apr; 19(4):215-222. PubMed ID: 37005129
[TBL] [Abstract][Full Text] [Related]
20. Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report.
Lasagna A; Lenti MV; Cassaniti I; Sacchi P
Immunotherapy; 2022 Aug; 14(12):915-925. PubMed ID: 35694999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
